Figure 5: In vitro cytotoxicity and therapeutic activity of BMAP-28 and its derivatives. | Scientific Reports

Figure 5: In vitro cytotoxicity and therapeutic activity of BMAP-28 and its derivatives.

From: Mechanistic and structural basis of bioengineered bovine Cathelicidin-5 with optimized therapeutic activity

Figure 5

(a) The graphs show the antimicrobial activity at various peptide concentrations on different Gram-positive and Gram-negative bacteria. The positive and negative controls represent cells in LB medium and LB media without cells, respectively. (b) The intracellular binding activity of target peptides studied using the luciferase synthesis assay. The luciferase synthesis without peptide (Cntrl -) and in presence of kanamycin (Cntrl+) is used. (c) Effect of peptides on the percentage growth inhibition of P. falciparum strain. The antimalarial drug artemisinin (Art) is used as a positive control. (d) Hemolytic activity of target peptides is studied using the percentage release of hemoglobin. Phosphate buffer (PBS) is used as a negative control for the RBC lysis assay. Anticancer activity of BMAP-28 and its analogues in (e) Jurkat, and (f) Ramos lymphoma cells. The cell-viability assay is measured using MTT reagent after 24, 48 and 72 h incubation.

Back to article page